Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

Income Statement

Follow revenue through to earnings.

Revenue

$107.46M

FY 2025 · Annual

+66.9% YoY

Operating Income

-$13.25M

FY 2025 · Annual

Net Income

$105.89M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

TBPH Earnings Waterfall · TTM

NASDAQ:TBPH · Revenue to Net Income

Key Ratios

EPS$2.20
Gross Margin77.0%
Net Margin83.1%
P/E Ratio3.8
P/S Ratio31.4

Analysis

$109.8M of revenue converted into $114.5M of net income for the selected period. Gross margin is 77.0% and net margin is 83.1%, showing how much revenue survives after costs and taxes. EPS is $2.20, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingSep 25, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
S-8 POSS-8 POS filingSep 24, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
4Statement of changes in beneficial ownershipSep 24, 2026

How much revenue does TBPH generate?

Theravance Biopharma, Inc. (TBPH) reported $107.46M of revenue in fiscal 2025.

Is TBPH profitable?

Theravance Biopharma, Inc. (TBPH) reported $105.89M of net income, with a net margin of 98.5%.